Kodiak Sciences (NASDAQ:KOD) Shares Gap Up After Analyst Upgrade

Kodiak Sciences Inc. (NASDAQ:KOD) shares gapped up prior to trading on Friday after UBS Group raised their price target on the stock from $50.00 to $80.00. The stock had previously closed at $39.76, but opened at $41.89. UBS Group currently has a buy rating on the stock. Kodiak Sciences shares last traded at $44.9810, with a volume of 1,727,148 shares traded.

KOD has been the topic of several other reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Kodiak Sciences in a research report on Thursday, January 22nd. HC Wainwright reissued a “buy” rating and set a $58.00 price objective (up from $38.00) on shares of Kodiak Sciences in a research report on Friday. Five equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $35.43.

Kodiak Sciences News Summary

Here are the key news stories impacting Kodiak Sciences this week:

• Positive Sentiment: Topline Phase 3 (GLOW2) win for Zenkuda: Kodiak reported that Zenkuda (tarcocimab tedromer) met the primary endpoint in GLOW2, showing a large improvement in diabetic retinopathy severity (62.5% of treated patients achieved ≥2‑step DRSS improvement vs 3.3% for sham) with a 6‑month dosing interval — a result that materially raises the drug’s efficacy and commercial prospects. PR Newswire
• Positive Sentiment: Market reaction: The GLOW2 news triggered large intraday rallies (reports of 50–75%+ moves) as traders repriced KOD for a potential regulatory filing and eventual launch. This surge reflected investor expectations that the program can support a Biologics License Application (BLA) and a valuable ophthalmology franchise. Reuters
• Positive Sentiment: Analyst upgrades and higher price targets: Following the data, UBS raised its price target to $80 with a Buy rating and HC Wainwright reaffirmed Buy while raising its target to $58 — both moves signal increased sell‑side conviction and provide further upside narrative for investors. Benzinga (UBS) TickerReport (HC Wainwright)
• Neutral Sentiment: Regulatory path and next steps: Coverage notes and industry press indicate a likely BLA filing is now the logical next step; timing and FDA interactions remain catalysts but are not guaranteed. Positive data increase probability, but approval and commercial uptake timelines still carry execution risk. BioWorld
• Negative Sentiment: Volatility and hedging activity: There was unusually high put option activity the day of the results (large put volumes vs typical), indicating some traders were hedging or positioning for downside — a sign of elevated speculative interest and potential for sharp intraday reversals. (Options flow reported 3,472 puts vs typical ~256.)
• Negative Sentiment: Today’s pullback amid heavy volume: After the strong rally on the data, the shares have pulled back today on very heavy trading — a common post‑news profit taking and volatility washout that increases short‑term risk despite the fundamentally positive trial news.

Institutional Trading of Kodiak Sciences

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Boone Capital Management LLC bought a new position in Kodiak Sciences during the third quarter valued at about $11,719,000. TD Asset Management Inc acquired a new stake in shares of Kodiak Sciences during the 3rd quarter worth approximately $992,000. Campbell & CO Investment Adviser LLC acquired a new stake in shares of Kodiak Sciences during the 3rd quarter worth approximately $488,000. Panagora Asset Management Inc. increased its position in shares of Kodiak Sciences by 28.5% during the second quarter. Panagora Asset Management Inc. now owns 131,122 shares of the company’s stock valued at $489,000 after purchasing an additional 29,113 shares during the period. Finally, Vanguard Group Inc. raised its stake in shares of Kodiak Sciences by 18.6% in the fourth quarter. Vanguard Group Inc. now owns 2,313,395 shares of the company’s stock valued at $64,683,000 after purchasing an additional 363,103 shares in the last quarter. 89.06% of the stock is currently owned by institutional investors and hedge funds.

Kodiak Sciences Price Performance

The firm has a market capitalization of $1.96 billion, a price-to-earnings ratio of -8.98 and a beta of 2.61. The business has a 50 day moving average of $25.14 and a 200 day moving average of $21.89.

About Kodiak Sciences

Kodiak Sciences, Inc is a clinical‐stage biopharmaceutical company headquartered in Palo Alto, California, that focuses on the discovery and development of novel therapies for retinal diseases. The company’s proprietary technology centers on antibody biopolymer conjugates (ABCs), which are designed to extend durability, enhance tissue penetration and improve the safety profile of existing therapeutic modalities. Kodiak’s research and development efforts target conditions such as wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and other serious ophthalmic disorders.

The lead product candidate in Kodiak’s pipeline is KSI-301, an anti-VEGF antibody biopolymer conjugate administered via intravitreal injection.